Prevention of antimicrobial prescribing among infants following maternal vaccination against respiratory syncytial virus

Proc Natl Acad Sci U S A. 2022 Mar 22;119(12):e2112410119. doi: 10.1073/pnas.2112410119. Epub 2022 Mar 14.

Abstract

SignificanceStrategies to reduce consumption of antimicrobial drugs are needed to contain the growing burden of antimicrobial resistance. Respiratory syncytial virus (RSV) is a prominent cause of upper and lower respiratory tract infections, as a single agent and in conjunction with bacterial pathogens, and may thus contribute to the burden of both inappropriately treated viral infections and appropriately treated polymicrobial infections involving bacteria. In a double-blind, randomized, placebo-controlled trial, administering an RSV vaccine to pregnant mothers reduced antimicrobial prescribing among their infants by 12.9% over the first 3 mo of life. Our findings implicate RSV as an important contributor to antimicrobial exposure among infants and demonstrate that this exposure is preventable by use of effective maternal vaccines against RSV.

Keywords: antimicrobial prescribing; antimicrobial resistance; randomized controlled trial; respiratory syncytial virus; vaccination.

Publication types

  • Randomized Controlled Trial

MeSH terms

  • Anti-Bacterial Agents
  • Anti-Infective Agents*
  • Female
  • Humans
  • Infant
  • Pregnancy
  • Respiratory Syncytial Virus Infections* / drug therapy
  • Respiratory Syncytial Virus Infections* / prevention & control
  • Respiratory Syncytial Virus Vaccines* / therapeutic use
  • Respiratory Syncytial Virus, Human*
  • Vaccination

Substances

  • Anti-Bacterial Agents
  • Anti-Infective Agents
  • Respiratory Syncytial Virus Vaccines